Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.
Jiangsu Hengrui Pharmaceuticals Co's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is
-164.37%.
Jiangsu Hengrui Pharmaceuticals Co Margin of Safety % (DCF Earnings Based) Related Terms
SHSE:600276 vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Margin of Safety % (DCF Earnings Based) falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.
What does a Margin of Safety % (DCF Earnings Based) of -164.37% mean?
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Margin of Safety % (DCF Earnings Based) of -164.37% as of Jun. 27, 2026. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Jiangsu Hengrui Pharmaceuticals Co.
Is Jiangsu Hengrui Pharmaceuticals Co's Margin of Safety % (DCF Earnings Based) too high?
Jiangsu Hengrui Pharmaceuticals Co's current Margin of Safety % (DCF Earnings Based) is -164.37%. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Margin of Safety % (DCF Earnings Based) compare to ZTS and UTHR?
Jiangsu Hengrui Pharmaceuticals Co's Margin of Safety % (DCF Earnings Based) of -164.37% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Earnings Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF Earnings Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Earnings Based) mean?
A high Margin of Safety % (DCF Earnings Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Jiangsu Hengrui Pharmaceuticals Co. Jiangsu Hengrui Pharmaceuticals Co's current Margin of Safety % (DCF Earnings Based) is -164.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.34, compared to a current price of ¥48.67 — trading 19.3% below its estimated fair value. The current Margin of Safety % (DCF Earnings Based) is -164.37%. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Earnings Based) calculated?
Margin of Safety % (DCF Earnings Based) is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Margin of Safety % (DCF Earnings Based) is -164.37% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥48.67 is trading 19.3% below its estimated GF Value™ of ¥60.34.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SHSE:600276:
Margin of Safety % (DCF Earnings Based): -164.37%
GF Value™: ¥60.34 vs. price of ¥48.67 (19.3% below fair value)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score
Get the complete analysis for SHSE:600276
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 